AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Absci Corporation (ABSI) Secures $64M Financing to Drive AI Drug Discovery Through 2028
ByAinvest
Sunday, Sep 21, 2025 9:29 am ET1min read
Absci Corporation (ABSI) raised $64m in equity financing to drive AI drug discovery through 2028. The funding will support the advancement of key pipeline programs, including ABS-101 and ABS-201, while accelerating partnered projects and strengthening the corporation's AI infrastructure. ABSI is pioneering the integration of deep learning with high-throughput lab automation to design and optimize biologics at scale. Its Integrated Drug Creation (IDC) platform combines proprietary algorithms with protein engineering, enabling rapid development of antibody and enzyme candidates for both pharma partners and its own pipeline.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet